Gulf Shores Dialysis Center is a medicare approved dialysis facility center in Gulf Shores, Alabama and it has 8 dialysis stations. It is located in Baldwin county at 3947 Gulf Shores Parkway, Gulf Shores, AL, 36542. You can reach out to the office of Gulf Shores Dialysis Center at (251) 967-2205. This dialysis clinic is managed and/or owned by Davita. Gulf Shores Dialysis Center has the following ownership type - Profit. It was first certified by medicare in April, 2009. The medicare id for this facility is 012631 and it accepts patients under medicare ESRD program.
| Name | Gulf Shores Dialysis Center |
|---|---|
| Location | 3947 Gulf Shores Parkway, Gulf Shores, Alabama |
| No. of Dialysis Stations | 8 |
| Medicare ID | 012631 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 3947 Gulf Shores Parkway, Gulf Shores, Alabama, 36542 | |
| (251) 967-2205 | |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
| NPI Number | 1811140767 |
| Organization Name | Gulf Shores Dialysis Center |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 3947 Gulf Shores Pkwy Gulf Shores, Alabama, 36542 |
| Phone Number | (251) 967-2205 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 16 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 6 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 26 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 217 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 9 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 64 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Gulf Shores Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 35 |
| Hypercalcemia patient months | 282 |
| Patients with Serumphosphor | 34 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 97 |
| Patient months included in arterial venous fistula and catheter summaries | 279 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 1 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 29 |
| Hospitalization Rate in facility | 138.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 331.7 |
| Hospitalization Rate: Lower Confidence Limit | 62.3 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Gulf Shores Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 45.4 |
| Readmission Rate: Lower Confidence Limit | 6.5 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Gulf Shores Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .84 (As Expected) |
| SIR: Upper Confidence Limit | 4.16 |
| SIR: Lower Confidence Limit | .04 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Gulf Shores Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 21 |
| Transfusion Rate in facility | 63.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 220.6 |
| Transfusion Rate: Lower Confidence Limit | 21.2 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Gulf Shores Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 139 |
| Mortality Rate in facility | 21.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 33 |
| Mortality Rate: Lower Confidence Limit | 13 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago
Gulf Shores Dialysis Center Location: 3947 Gulf Shores Parkway, Gulf Shores, Alabama, 36542 Phone: (251) 967-2205 |
News Archive
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.
Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Researchers have identified the mechanism of action of lipoic acid, a remarkable compound that in animal experiments appears to slow down the process of aging, improve blood flow, enhance immune function and perform many other functions.
› Verified 2 days ago